PREVAIL Act Reintroduced The PREVAIL Act to Address

Posted on Sat/3/MaySat/3/May by AZBio

The Promoting and Respecting Economically Vital American Innovation Leadership (PREVAIL) Act supports American inventors, encourages investments in intellectual property, secures U.S. global technology leadership, and safeguards both economic and national security.

“The PREVAIL Act will empower startups and small businesses by realigning the Patent Trial and Appeals Board with Congress’s original intent,” — Dr. Hans Sauer, Deputy General Counsel and Vice President for Intellectual Property, Biotechnology Innovation Organization (BIO).

Continue reading→

CND Life Sciences Closes $13.5M Series A Equity Round to Continue Growth and Innovation in Neurodiagnostics

Posted on Thu/1/MayThu/1/May by AZBio

Latest Series A3 financing includes Labcorp, along with new and longtime investorsContinue reading→

NIH to prioritize human-based research technologies

Posted on Tue/29/AprilTue/29/April by AZBio

New initiative aims to reduce use of animals in NIH-funded research.Continue reading→

AdvaMed CEO Calls for “Zero for Zero” Reciprocal Tariffs on Medtech with U.S. Trading Partners

Posted on Sun/27/AprilSun/27/April by AZBio

WASHINGTON, April 25, 2025 – Scott Whitaker, president and CEO of AdvaMed, the Medtech Association, today called for a reciprocal “zero for zero” model with respect to tariffs among U.S. trading partners for medical technologies. In an interview with Joe Mullings of the Mullings Group, Whitaker stated that tariff-free trade is critical to maintaining the highly competitive nature of the medtech industry, which keeps prices down and serves patients nationwide and globally with a robust breadth and depth of lifesaving medtech. Continue reading→

First-of-Its-Kind Cancer Therapy Targets ‘Undruggable’ Protein Interaction

Posted on Sat/26/AprilSat/26/April by AZBio

A groundbreaking cancer therapy being developed in Phoenix is rewriting the rules of drug discovery by targeting what scientists have long considered “undruggable”— a critical interaction between two proteins that drive tumor growth and spreadingContinue reading→

NSF Director Sethuraman Panchanathan Resigns

Posted on Fri/25/AprilFri/25/April by AZBio

Dr. Sethuraman “Panch” Panchanathan announced on April 24, 2025 his decision to “step down as Director of the U.S. National Science Foundation (NSF), effective today.” He was in the fifth year of his six year appointment.

Continue reading→

Arizona’s Bioscience Roadmap 2025 Progress Update

Posted on Thu/24/AprilThu/24/April by AZBio

On April 23, 2025, the Flinn Foundation releases this year’s Progress Report on Arizona’s Bioscience Roadmap included new data on bioscience performance metrics from TEConomy Partners, an update on the University of Arizona’s strategic directions, and a look at the new Roadmap from SRI International.

Continue reading→

Roche to invest USD 50 billion in pharmaceuticals and diagnostics in the United States over the next five years

Posted on Tue/22/AprilTue/22/April by AZBio

USD 50 billion commitment includes new state-of-the art research and development (R&D) sites, new and expanded manufacturing facilities in Indiana, Pennsylvania, Massachusetts and California and an additional site location to be announced soon
Investments will create more than 12,000 new jobs: 1,000 at Roche and more than 11,000 in support of new US manufacturing capabilities
Roche already has a significant existing US presence with more than 25,000 employees, 15 R&D centres and 13 manufacturing sites

Continue reading→

The University of Arizona announces two strategic academic realignments that will take effect on July 1:

Posted on Sat/19/AprilSat/19/April by AZBio

The College of Health Sciences will be integrated into the Mel and Enid Zuckerman College of Public Health as a new School of Health Professions and Global Medicine.
The College of Applied Science and Technology will be integrated into the College of Information Science.

Continue reading→